Transdermally delivered peroxovanadium can lower blood glucose levels in diabetic rats

International Journal of Pharmaceutics

Volumn 183, Issue 2, 1999, Pages 117-123

  Brand, Rhonda M ^a,b,c   Hamel, Frederick G ^b,c  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b Section of Transplantation   (United States)

^c VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Blood glucose; In vivo; Iontophoresis; Peroxovanadium; Rat; Transdermal drug delivery; Vanadium

Indexed keywords

VANADATE SODIUM; VANADIUM DERIVATIVE; VANADYL SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INSULIN SENSITIVITY; IONTOPHORESIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIFFUSION; IONTOPHORESIS; MALE; ORGANOMETALLIC COMPOUNDS; PHENANTHROLINES; RATS; RATS, SPRAGUE-DAWLEY; SKIN ABSORPTION; TIME FACTORS;

EID: 0032993885     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00071-X     Document Type: Article

References (33)

1. Bevan A.P., Drake P.G., Yale J.F., Shaver A., Posner B.I. Peroxovanadium compounds: biological actions and mechanism of insulin mimesis. Mol. Cell Biochem. 153:1995;49-58.
2. Bevan A.P., Burgess J.W., Yale J.F., Drake P.G., Lachance D., Baquiran G., Shaver A., Posner B.I. In vivo insulin mimetic effects of pV compounds: role for tissue targeting in determining potency. Am. J. Physiol. 268:1995;E60-E66.
3. Blotcky A.J., Duckworth W.C., Ebrahim A., Hamel F.G., Sharma R.G.B., Rack E.P. Determination of vanadium in serum by pre-irradiation and post-irradiation chemistry and neutron activation analysis. J. Radioanal. Nucl. Chem. 134:1989;151-160.
4. Brand R.M., Duensing G., Hamel F.G. Iontophoretic delivery of an insulin-mimetic peroxovanadium compound. Int. J. Pharm. 146:1997;115-122.
5. Brichard S., Lederer J., Henquin J. The insulin-like properties of vanadium: a curiosity or a prospective for the treatment of diabetes? Diab. Metabol. 17:1991;435-440.
6. Brichard S.M., Bailey C.J., Henquin J.C. Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes. 39:1990;1326-1332.
7. Butler A. The coordination and redox chemistry of vanadium in aqueous solution. Chasteen N.D. Vanadium in Biological Systems. 1990;25-49 Kluwer, Dordrecht.
8. Cohen M., Parsons E., Schlesinger R., Zelikoff J. Immunotoxicity of in vitro vanadium exposures: effects on interleukin-1, tumor necrosis factor-, and prostaglandin E2 production by WEHI-3 macrophages. Int. J. Immunopharmacol. 15:1993;437-446.
9. Cohen N., Halberstam M., Shlimovich P., Chang C.J., Shamoon H., Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 95:1995;2501-2509.
10. Cullander C., Guy R.H. Routes of delivery: case studies(6). Transdermal delivery of peptides and proteins. Adv. Drug Del. Rev. 8:1992;291-329.
11. Domingo J., Gomez M., Llobet J., Corbella J., Keen C. Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are independent of the form of vanadium used. Toxicology. 66:1991;279-287.
12. Dubyak G.R., Kleinzeller A. The insulin-mimetic effects of vanadate in isolated rat adipocytes. J. Biol. Chem. 255:1980;5306-5312.
13. Goldfine A.B., Simonson D.C., Folli F., Patti M.E., Kahn C.R. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol. Cell. Biochem. 153:1995;217-231.
14. Goldfine A.B., Simonson D.C., Folli F., Patti M.E., Kahn C.R. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus: In vivo and in vitro studies. J. Clin. Endocrinol. Metab. 80:1995;3311-3320.
15. Haga M., Akatani M., Kikuchi J., Ueno Y., Hayashi M. Transdermal iontophoretic delivery of insulin using a photoetched microdevice. J. Controlled Rel. 43:1997;139-149.
16. Halberstam M., Cohen N., Shlimovich P., Rossetti L, Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes. 45:1996;659-666.
17. Hamel F.G. Endocrine control of vanadium accumulation. Nriagu J.O. Vanadium in the Environment. 1998;265-276 Wiley, New York.
18. Hamel F.G., Duckworth W.C. The relationship between insulin and vanadium metabolism in insulin target tissues. Mol. Cell. Biochem. 153:1995;95-102.
19. Heyliger C.E., Tahiliani A.G., McNeill J.H. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science. 227:1985;1474-1477.
20. Ledger P.W. Skin biological issues in electrically enhanced transdermal delivery. Adv. Drug Del. Rev. 9:1992;289-307.
21. Leonard A., Gerber G. Mutagenicity, carcinogenicity, and teratogenicity of vanadium compounds. Mutat. Res. 317:1994;81-88.
22. Meyerovitch J., Farfel Z., Sack J., Schechter Y. Oral administration of vanadate normalizae blood glucose levels in streptozotocin-treated rats: characteristics and mode of action. J. Biol. Chem. 262:1987;6658-6662.
23. Mitragotri S., Blankschtein D., Langer R. Ultrasound-mediated transdermal protein delivery. Science. 269:1995;850-853.
24. Nathan D.M., Singer D.E., Hurxthal K., Gordson J.D. The clinical information value of the glycosylated hemoglobin assay. N. Engl. J. Med. 310:1984;341-346.
25. Pederson R.A., Ramanadham S., Buchan A.M., McNeill J.H. Long-term effects of vanadyl treatment on streptozotocin-induced diabetes in rats. Diabetes. 38:1989;1390-1395.
26. Posner B.I., Faure R., Burgess J.W., Bevan A.P., Lachance D., Zhang-Sun G., Fantus I.G., Ng J.B., Hall D.A., Lum B.S., Shaver A. Peroxovanadium compounds, a new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J. Biol. Chem. 269:1994;4596-4604.
27. Schechter Y., Karlish S.J.D. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature. 284:1980;556-558.
28. Shechter Y. Insulin mimetic effects of vanadate: possible implication for future treatment of diabetes. Diabetes. 39:1990;1-5.
29. Shechter Y., Shisheva A. Vanadium salts and the future treatment of diabetes. Endeavor. 17:1993;27-31.
30. Singh P, Maibach HI. Iontophoresis in drug delivery: basic principles and applications. Crit. Rev. Ther. Drug Carrier Syst. 11:1994;161-213.
31. Tachibana K. Transdermal delivery of insulin to alloxan-diabetic rabbits by ultrasound exposure. Pharm. Res. 9:1992;952-954.
32. Tomohira Y., Machida Y., Onishi H., Nagai T. Iontophoretic transdermal absorption of insulin and calcitonin in rats with newly-devised switching technique and addition of urea. Int. J. Pharm. 155:1997;231-239.
33. Willsky G.R. Vanadium in the Biosphere. Chasteen N.D. Vanadium in Biological Systems. 1990;1-24 Kluwer, Dordrecht.